In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Senti Biosciences (SNTI – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $1.25.
Ulz covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Rocket Pharmaceuticals, and Ionis Pharmaceuticals. According to TipRanks, Ulz has an average return of -0.5% and a 40.25% success rate on recommended stocks.
Senti Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
Based on Senti Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 million and a GAAP net loss of $16.64 million. In comparison, last year the company earned a revenue of $778 thousand and had a GAAP net loss of $12.01 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynamics Special Purpose Corp is a blank check company.
Read More on SNTI:
- Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
- Senti Bio reports Q4 EPS (42c), consensus (44c)
- Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
- Senti Biosciences Announces New Employment Inducement Grants
- Senti Bio to Present at the SVB Securities Global Biopharma Conference
